Fractyl Health (GUTS) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
24 Sep, 2026Opening remarks and agenda
Meeting opened by CEO and Chairperson, with introductions of board members and key company officers.
Agenda and rules of conduct were made available on the virtual meeting webpage.
Specific resolutions to be voted on
Only one proposal was presented: approval of alternate amendments to the certificate of incorporation to allow a reverse stock split at a ratio between 1-for-5 and 1-for-15, at the board's discretion.
Corporate governance
Proof of mailing of notice and compliance with Delaware law and company bylaws was confirmed.
Inspector of Election was sworn in to ensure impartiality and oversee voting.
Quorum was established with over 70% of shares represented.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Fractyl Health
- Revita aims to transform post-GLP-1 weight maintenance with pivotal data and U.S. launch targeted for 2028.GUTS
Morgan Stanley 24th Annual Global Healthcare Conference - Revita shows promise for durable weight maintenance post-GLP-1, with pivotal data due Q4 2026.GUTS
H.C. Wainwright 28th Annual Global Investment Conference - A scalable, high-margin procedure addresses the urgent post-GLP-1 weight maintenance gap.GUTS
Status update - Revita offers a scalable, cost-effective solution for post-GLP-1 weight maintenance with rapid path to profitability.GUTS
Corporate presentation - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.GUTS
Proxy filing - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.GUTS
Proxy filing - Revita nears pivotal data for post-GLP-1 weight maintenance as Rejuva enters clinical trials.GUTS
Canaccord Genuity's 46th Annual Growth Conference - Revita maintained up to 84% of GLP-1 weight loss; net loss narrowed, but liquidity risks persist.GUTS
Q2 2026 - Revita enabled up to 84% weight loss retention at one year post-GLP-1, with strong safety data.GUTS
Study result